Document is current
Any future updates will be listed below
-
Authors
García-Bernal, David http://orcid.org/0000-0001-6610-8442
Blanquer, Miguel
Martínez, Carlos M. http://orcid.org/0000-0003-3307-1326
García-Guillén, Ana I. http://orcid.org/0000-0002-1824-9272
García-Hernández, Ana M.
Carmen Algueró, M.
Yáñez, Rosa http://orcid.org/0000-0003-0132-3402
Lamana, María L.
Moraleda, Jose M. http://orcid.org/0000-0001-9080-1466
Sackstein, Robert http://orcid.org/0000-0003-1757-891X
-
Funding
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI13/00184, RD12/0019/0001, RD12/0019/0023, RD16/0011/0001)
- License Information
-
More Information
Article History
Received: 4 May 2022
Accepted: 5 October 2022
First Online: 19 October 2022
Competing interests
: According to National Institutes of Health policies and procedures, the Brigham & Women’s Hospital has assigned intellectual property rights regarding cell surface glycan engineering to R.S. R.S.’s ownership interests were reviewed and are managed by the Brigham & Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policy. All other authors declare that they have no competing interests.
